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This study explored the predictors of weight loss following orlistat with a focus on both baseline variables and changes in beliefs
and behaviours occurring over the course of taking the drug. Patients (n = 566) prescribed orlistat completed a questionnaire at
baseline and after 6 months concerning their weight, beliefs and behaviours. By 6 months the majority had lost some weight and
showed improvements in diet. Many had also stopped taking the drug and a large minority reported using it ﬂexibly as a lifestyle
drug. Those who lost most weight showed a decrease in beliefs in a medical solution, a decrease in unhealthy eating, an increased
beliefintreatmentcontrolandanincreasedbelief thattheunpleasantconsequences arebothduetotheireatingbehaviour andjust
part of the drug. When taken with fatty food orlistat causes symptoms such as anal leakage and oily stools. These may encourage
some patients to focus on the behavioural aspects of their weight problem thus promoting the dietary changes needed for both
short and longer term weight loss. When prescribing orlistat, clinicians should encourage patients to see the consequences as an
education as a means to promote the eﬀectiveness of this form of medical management.
1.Introduction
Orlistat (Xenical) is currently the only available form of
prescribed obesity medication which acts on the gastroin-
testinal system and works by reducing fat absorption in the
gut which is eliminated in bowel movements. It also blocks
the availability of fat-soluble vitamins (vitamins A, D, E,
and K), so patients may also take a vitamin supplement
[1, 2]. Current recommendations suggest that it is used for
patients who have a history of failed weight-loss attempts
using behavioural methods and who can demonstrate at
least 2.5kg weight loss by diet and exercise in the month
prior to their ﬁrst prescription [1]. It is suggested that
patients reduce their daily calorie intake by 500 to 1000
calories to promote weight loss, and the Dietary Guidelines
for Americans recommend that dietary fat is limited to
about 30% of daily calories. As a result of its impact upon
fat absorption, orlistat has unpleasant side eﬀects including
liquid stools, an urgency to go to the toilet, and anal leakage
which are particularly apparent following a high-fat meal as
the drug causes the fat consumed to be removed from the
body. Between 1998 and 2005, orlistat prescriptions rose 36-
fold from 17,880 to 646,700 and the total cost increased by
over 35-fold. Recent years have seen an additional signiﬁcant
increase in the number and cost of prescriptions for orlistat
[3].
Research has explored the eﬀectiveness of orlistat com-
pared to other drug treatments, placebo, or behaviour-fo-
cused interventions. For example, Padwal et al. [4]r e p o r t e d
that patients taking orlistat lost 2.7kg more than patients
taking placebo, and Avenell et al. [5] carried out a systematic
review of trials involving a combination of diets, drug
therapy, exercise, and behaviour therapy and concluded that
adding orlistat to a dietary intervention improved weight
loss by 3.26kg up to 24 months. Research also indicated
that orlistat reduces cholesterol and blood pressure levels
and improves glycemic control when compared to placebo
[4]. Similarly, Phelan and Wadden [6] concluded from
their review that adding orlistat to lifestyle modiﬁcation
interventions improves both weight loss and weight-loss
maintenance. Furthermore, in a recent updated meta-
analysis, Rucker et al. [7] synthesised the results of ran-
domised placebo- controlled trials of approved antiobesity
drugs in adults aged 18 and over for one to four years. They
concluded that with the active drug treatments patients were
more likely to reach 5% and 10% weight-loss thresholds2 Journal of Obesity
and that weight losses for three key drugs were as follows:
sibutramine: 4.2kg; rimonabant: 4.7kg, and orlistat: 2.9kg.
Research therefore indicates that orlistat can improve weight
loss if used alongside behavioural and lifestyle interventions.
There remain, however, two main problems with orlistat
as a treatment for obesity. First, although evidence indicates
that it can improve weight-loss outcomes, these improve-
mentsarenotalwayssubstantialandthereismuchvariability
with many patients showing no improvements at all. Second,
research also indicates high attrition rates with patients not
adhering to their medication due to the unpleasant side
eﬀects and many stoppings taking the drug entirely or using
it selectively according to the content of their diet. For
example, Padwal et al. [4] concluded from their review of
randomised control trials that the mean attrition rate for
orlistat was 33% (11 studies, n = 6021), and Vray et al.
[8] suggested that in clinical practice attrition rates are
even higher at 64%–77%. Research has therefore addressed
whether the eﬀectiveness of orlistat can be improved, and
some studies have explored whether speciﬁc patients beneﬁt
more than others and whether baseline variables predict
outcomes. However, whereas research exploring alternative
forms of medical management has explored a range of clin-
ical, psychological, and behavioural variables as predictors
of outcomes (e.g., [9–11]),research focusing on orlistat has
mainly emphasised laboratory and clinical variables [12].
In general, however, such studies conclude that the best
predictor of outcome following medical management is
initial weight loss, but to date few studies have explored
psychological and behavioural predictors of outcome fol-
lowing orlistat. An alternative approach has addressed the
mechanisms of how orlistat works, and from a medical
perspective the main consequence of orlistat is to reduce
fat absorption in the gut. However, due to the unpleasant
side eﬀects, Finer has labelled it the “antabuse eﬀect” [13]
as it deters the intake of high-fat foods. Further, Ogden and
Sidhu [14] carried out a qualitative study with patients who
had taken orlistat to explore their beliefs about why it either
did or did not facilitate weight loss. The results showed
that inline with previous research some patients stopped
taking their medication due to the unpleasant symptoms
such as anal leakage or oily stools. However, the results
also showed that these highly visual side eﬀects encouraged
some people to consider their behaviour as a cause of their
obesity. Many obese people focus on medical causes of their
problem such as hormones and genetics [15, 16]. The results
from this qualitative study of orlistat users indicated that by,
showing patients the fat they have consumed, orlistat can
shift patient models of obesity towards a more behavioural
perspective, thus encouraging them to adopt a healthier
diet. Leventhal et al. [17] described the notion of coherence
between beliefs about causes and solutions to any particular
medical problem. Inline with this, Ogden and Sidhu [14]
argued that orlistat functions by educating patients and
creatingcoherencebetweenbehaviouralcausesandtherefore
behavioural solutions for obesity. To date, however, this
process remains untested in a larger quantitative study.
In summary, although orlistat is currently the most com-
monly prescribed medication for the obese, there remains
much variability in its eﬀectiveness with only a minority of
patientsshowingweightloss.Researchhasthereforeexplored
the possible reasons for the eﬀectiveness of orlistat, and
whereas some studies have emphasised baseline characteris-
tics,othershavehighlightedchangesinbeliefsandbehaviour
brought about by the mechanisms of the drug itself. To date,
however, such studies have focused either on drugs other
than orlistat, have been limited in their choice of variables,
or have used small qualitative designs. The present study,
therefore, aimed to explore weight loss following a 6-month
course of orlistat and to explore the role of demographics,
beliefs, and behaviour in predicting outcomes in a large
sample of patients. Furthermore, inline with a focus on
mechanisms, the study aimed to assess the role of both
baseline variables and the changes occurring whilst orlistat
was being taken.
2. Method
2.1. Design. The study used a longitudinal design with
measuresconcerningBMI,experiencesoftakingorlistat,and
beliefs and behaviour being completed at baseline and six-
month followup.
2.2. Sample. Participants who had been prescribed orlistat
by the GP and registered on the Xenical support system
(MAP)fundedbyRochewereinvitedtotakepartinthestudy
and sent the baseline questionnaire. Those who returned
the baseline questionnaire were sent a further questionnaire
at six months. Only those who completed the baseline
questionnaire within the ﬁrst three months of starting to
take the medication and returned the 6 month followup
questionnaire were included in this study. 566 participants
returned both the baseline questionnaire within the ﬁrst
three months of starting to take orlistat and the 6 month
followup questionnaire. This represented a response rate
of 36% of total baseline responders. The University Ethics
Committee approved the study. The data presented here
reﬂect the short-term followup from baseline to six months.
2.3.Procedure. MAPgainedinitialconsentfromparticipants
to pass on their contact details to take part in the study.
An information sheet and questionnaire were then sent out
to participants by post. Those who returned the baseline
questionnaire were sent a similar followup questionnaire at
six months.
2.4. Measures. Baseline and followup questionnaires exam-
ined demographics, beliefs about obesity, beliefs about
side eﬀects, and behaviour. All beliefs and behaviour were
assessed using items which were rated using a 5-point Likert
scale ranging from “not at all” (1) to “totally” (5). For
each construct the individual items were summated and the
reliability of each construct was assessed using Cronbach’s
alpha. Most alphas were above the established cutoﬀ level
illustrating acceptable reliability. Some were lower, but this
is generally acceptable if there is diversity in the constructs
being measured.Journal of Obesity 3
(1) Demographics: participants completed measures of
weight, height, BMI, age, sex, and employment.
(2) Beliefs about obesity: this included measures relating
to (i) behavioural causes of obesity (α = .671)
(e.g., “eating too much,” “not enough exercise”);
(ii) medical causes of obesity (α = .659) (e.g.,
“genetics/inheritance,” “slow metabolism”); (iii)
behavioural solutions to obesity (α = .850) (e.g.,
“eating fewer calories,” “being more active”); (iv)
medical solutions to obesity (α = .630) (e.g.,
“medication,” “surgery”); (v) personal control over
weight (e.g., “how much control do you think you
have over your weight”); (vi) treatment control over
weight (e.g., “how much do you think Xenical can
help your weight?”).
(3) Beliefs about side eﬀects: participants rated (i) the
extenttowhichtheyhadexperiencedsideeﬀects(α =
.761) (e.g., “liquid stools,” “bloating”), (ii) the extent
to which they believed these side eﬀects were part
of the drug (α = .671) (e.g., “they are a necessary
part of taking the drug”), and (iii) whether the side
eﬀects were caused by eating behaviour (α = .826)
(e.g., “they have made me realise what is in diﬀerent
foods”).
(4) Behaviour: participants rated their behaviour in
terms of (i) adherence to medication (α = .577)
(e.g., “I take it religiously,” “I stop taking it before a
fatty meal” (which was reverse scored)), (ii) healthy
eating(α = .580)(e.g.,healthysnacks(e.g.,ricecakes,
crackers,andfruit),healthycooking(e.g.,boil,steam,
and cooked meals at home), and healthy food choices
(e.g., skimmed milk, low-fat cheese, and high intake
of fruit and vegetables) (iii) unhealthy eating (α =
.547) (e.g., unhealthy snacks (e.g., crisps, cakes, and
chocolate), unhealthy cooking (e.g., shallow fry, deep
fry, processed foods), and unhealthy food choices
(e.g., full-cream milk, full-fat butter/margarine, and
low intake of fruit and vegetables).
A l lm e a s u r e sr e l a t e dt ot h ep a s tm o n t hw e r eb a s e do n
previous qualitative research which has explored people’s
beliefs and experiences of taking obesity medication and
successful weight loss and maintenance [14, 18]. Participants
also completed the personal and treatment control items
of the brief Illness Perception Questionnaire that assesses
participants’ beliefs about their illness [19]. In addition the
healthy and unhealthy eating measures were taken from the
World Health Organisation 2001/02 protocol [20], the food
frequency questionnaires found in the study by Inchley et al.
[21], the seven-day food diary [22], and consumer market-
research report data [23].
2.5. Inclusion/Exclusion Criteria. Participants were included
if they registered with the MAP program within a four-
monthperiod,were18yearsorover,andhadbeenprescribed
orlistat by their GP and if they had completed the baseline
questionnairewithintheﬁrstthreemonthsofstartingtotake
orlistat and also returned the followup questionnaire at six
months.
2.6. Data analysis. The data were analysed to describe the
participants’ demographics, diﬀerences between responders
and nonresponders, and overall changes in BMI, weight,
and behaviour. Further, the data were analysed to assess
the role of baseline demographics, beliefs, and behaviour in
predicting improvements in BMI and to assess the role of
changes in beliefs and behaviour over the course of 6 months
in predicting improvement in BMI by 6 months.
3. Results
3.1. Participants’ Demographics and Responders versus Non-
responders. Responders’, to the questionnaire, versus nonre-
sponders’ (at 6 months) demographic variables are shown in
Table 1.
The results showed that the mean age of the people
who returned a completed questionnaire at both time
points (responders) was 50 years and that the majority
were white, female, not working, married, educated up
until college, and with a mean BMI of 36. Further, the
responders and nonresponders (those who returned the
baseline questionnaire but not the followup questionnaire at
6 months) were comparable on all baseline demographics
apart from age with the responders being older than the
nonresponders.
3.2. Overall Changes in BMI, Weight, and Behaviour. Change
scores for BMI, beliefs, and behaviour were calculated (T1-
T2) and then classiﬁed into groups: weight loss versus no
weight loss; decrease in BMI versus no decrease in BMI;
improvement in healthy eating versus no improvement;
increased unhealthy eating versus no increase, and for
adherence those who had stopped taking it by 6 months were
grouped as “nonadherers”, those who rated their adherence
as “totally” were rated as “adherers”, and those who reported
ﬂexible adherence according to what they were eating were
recoded as “lifestyle adherers.” These results are shown in
Table 2.
The results showed that by 6 months the majority of
the responders had lost weight and decreased their BMI.
The mean weight loss was 4.09kg (SD: 6.21), the median
weight loss was 3.63kg, and percentage weight losses were
as follows: 0–2kg: 19.36%; 2.1–5kg: 28.1%; 5.1–7kg: 15.9%;
7.1–10kg: 17.4%; 10.1kg: 19.3%. In addition, the majority
had increased their healthy eating and decreased their
unhealthy eating and were no longer taking orlistat although
a large minority reported either full adherence or being
lifestyle users by 6 months.
3.3. Predictors of Improvement in BMI over 6 Months. The
results were then analysed to assess the role of beliefs
and behaviour in predicting an improvement in BMI by
6 months both in terms of baseline and change scores
using Multiple Regression Analysis and using forced entry
method.4 Journal of Obesity
Table 1: Responders versus nonresponders at baseline.
Variable Responders (n = 568) Nonresponders (n = 1008) t/χ2 P
Age x = 50.24 x = 47.60 14.59 .0001
∗
SD = 13.01 SD = 13.11
n = 560 n = 993
Sex Male = 98 (17.5%) Male = 181 (18.1%) .109 .741
Female = 463 (82.5%) Female = 817 (81.9%)
Ethnicity White = 543 (97.1%) White = 950 (94.8%) 4.705 .319
Black Caribbean = 4 (0.7%) Black Caribbean = 14 (1.4%)
Black African = 2 (0.4%) Black African = 7 (0.7%)
Asian = 5 (0.9%) Asian = 16 (1.6%)
Other = 5 (0.9%) Other = 15 (1.5%)
Job Full time = 174 (31.6%) Full time = 324 (33.5%) .935 .627
Part time = 113 (20.5%) Part time = 204 (21.1%)
Not Working = 264 (47.9%) Not Working = 439 (45.4%)
Marital Status Married = 330 (59.6%) Married = 598 (61.5%) 1.370 .849
Divorced = 66 (11.9%) Divorced = 122 (12.6%)
With Partner = 64 (11.6%) With Partner = 98 (10.1%)
Single = 71 (12.8%) Single = 118 (12.1%)
Widowed = 23 (4.2%) Widowed = 36 (3.7%)
Education <secondary = 68 (12.4%) <secondary = 125 (13.2%) 9.525 .146
Sec Sch Grad = 178 (32.5%) Sec Sch Grad = 332 (35%)
Some Coll = 133 (24.3%) Some Coll = 239 (25.2%)
Coll Grad = 78 (14.3%) Coll Grad = 140 (14.8%)
Graduate = 54 (9.9%) Graduate = 54 (5.7%)
Postgraduate = 12 (2.2%) Postgraduate = 21 (2.2%)
Doct/Prof = 24 (4.4%) Doct/Prof = 37 (3.9%)
BMI x = 36.20 x = 35.98 .452 .501
SD = 5.84 SD = 6.01
n = 527 n = 948
Table 2: Descriptive analysis of baseline to 6 months data.
No Yes Lifestyle
Lose weight n = 131 26.4% n = 365 73.6%
Range =− 18 to 0.07 Range = 0.08 to 25
Decrease in BMI n = 128 26% n = 364 74%
Range =− 6.15 to 0.02 Range = 0.03 to 9
Increased healthy eating n = 187 41.7% n = 261 58.3%
Range =− 8t o0 . 0 7 R a n g e= 0.08 to 13
Increased unhealthy eating n = 318 74.1% n = 111 25.9%
Range =− 8t o0 . 0 7 R a n g e= 0.08 to 5
Adherence n = 194 n = 124 n = 90
47.5% 30.4% 22.1%
3.3.1. Baseline Predictors of BMI Improvement. T h er o l eo f
baseline beliefs and behaviour in predicting improvements
in BMI are shown in Table 3.
The results showed that an improvement in BMI was
predicted by a greater endorsement of a medical solution to
their weight problem at baseline, accounting for 7.9% of the
variance (F = 2.862, P = .001). No other baseline variables
were signiﬁcant.
3.3.2. Changes in Beliefs and Behaviour as Predictors of BMI
Improvement. Change scores in beliefs and behaviour were
calculated (T1-T2). The role of these variables in predicting
improvements in BMI is shown in Table 4.
The results showed that a decrease in BMI over 6 months
was predicted by a decrease in endorsing a medical solution
to their weight problem, a decrease in unhealthy eating, an
increased belief in treatment control, and an increased beliefJournal of Obesity 5
Table 3: Baseline predictors of a decrease in BMI over 6 months.
Variables Standardised
β coeﬃcient P
Age .082 .194
Sex .072 .234
Behavioural cause −.100 .161
Medical cause −.048 .430
Behavioural solution .078 .267
Medical solution .157 .012
∗
Treatment control .044 .527
Personal control .078 .217
Experience of side eﬀects −.134 .066
Side eﬀects part of the drug −.001 .984
Side eﬀects due to eating behaviour −.032 .621
Healthy diet .018 .766
Unhealthy diet −.125 .054
Adjusted
R2 = .079
Table 4: Change scores as predictors of improvements in BMI over
6m o n t h s .
Variables Standardised
β coeﬃcient P
Change in behavioural cause .123 .151
Change in medical cause .013 .866
Change in behavioural solution −.004 .963
Change in medical solution .228 .004
∗
Change in treatment control −.259 .001
∗
Change in personal control −.052 .498
Change in experience of side eﬀects −.020 .810
Change in side eﬀects part of the drug −.167 .039
∗
Change in side eﬀects due to eating
−.218 .005
∗
behavior
Change in healthy eating .115 .129
Change in unhealthy eating .183 .017
∗
Adjusted
R2 = .173
that the side eﬀects are both due to their eating behaviour
and just part of the drug, accounting for 17.3% of the
variance (F = 4.015, P = .0001).
4. Discussion
The present study aimed to explore the predictors of weight
loss following 6 months after being prescribed orlistat with
a focus on both baseline variables and changes in beliefs and
behaviour over the course of taking the drug.
The results showed that by the end of 6 months
three quarters of patients reported both weight loss and a
reduction in their BMI with the majority falling within the
expectedrangeinlinewithpreviousoutcomestudies[4,5,7].
The majority also reported an increase in healthy eating
and a decrease in unhealthy eating which provides some
support for the impact of orlistat on diet and its use as the
“antabuse eﬀect” [13]. Furthermore, just less than half had
stopped taking their medication by 6 months, and a large
minorityreportedusingitﬂexiblyinresponsetotheirdietary
choices which is consistent with high attrition rates found
in previous studies and the use of orlistat as a lifestyle drug
[4, 8].
In terms of predictors of outcomes, only one baseline
variable was related to a reduction in BMI by six months.
In particular, the results showed that a greater endorsement
of a medical solution to obesity predicts a greater reduc-
tion in BMI by followup indicating that those who have
greater expectations of success for the drug show greater
improvements. This ﬁnds reﬂection in the focus on baseline
predictors reported for other forms of medical management
(e.g., [9, 10]) but suggests that it would be diﬃcult to proﬁle
those patients at baseline who would most beneﬁt from
taking the drug.
The data were also analysed, however, to explore the role
of changes in beliefs and behaviour over the course of taking
orlistat and produced more promising results. In particular,
those who lost most weight showed a decrease in beliefs
in a medical solution, a decrease in unhealthy eating, an
increased belief in treatment control, and an increased belief
that the side eﬀects are both due to their eating behaviour
and just part of how the drug works. Therefore, it would
seem that taking orlistat may encourage patients to focus on
their behaviour rather than medical factors as solutions to
obesity and subsequently improve their diet and that if such
changes in beliefs and behaviour occur, weight loss is greater.
This provides quantitative support for previous smaller-scale
qualitative research [14] and indicates that the highly visual
side eﬀects of orlistat, while being unpleasant and a deterrent
for some users, for others may help educate them towards a
more behavioural focus on their weight problem.
There are some issues with the study which need to be
addressed. First, the study did not include a control group
as the study aimed to explore the predictors of outcomes
after taking orlistat rather than to assess the eﬀectiveness of
this drug. The eﬀectiveness of the drug has been explored
elsewhere [4]. Second, both diet and weight were assessed
using self-report rather than an objective measurement tool.
This means that there may well be inaccuracies in the data
as research has shown that people tend to underestimate
both their weight and what they eat. However, for the
present study such self-report measures represented the
best means of measuring these variables in a large-scale
nationwide survey as it would not have been feasible to
call all participants into the clinic to collect more objective
data. Third, due to the recruitment procedure, participants
were generally completing the questionnaires within the ﬁrst
3 months of taking orlistat. The baseline data, therefore,
reﬂects their beliefs and experiences at the start of their
course of taking orlistat but does not reﬂect that, either
before or at the very start of this process. Future research
should aim to recruit participants just before they take their
ﬁrst prescription of orlistat in order to gain a true baseline.
Finally, the data does not show exactly when the participants6 Journal of Obesity
stopped taking orlistat. However, by followup it is known
whether the participants were currently taking the drug
or if they had stopped within the last month. Therefore,
although we do not have an exact marker of when the course
of medication was stopped and therefore when its impact
upon beliefs and behaviour ceased to occur, we do have
an approximate measure which enables some assessment
of the interrelationships between drug use and beliefs and
behaviour change. Given these limitations, however, the
study does provide some insights into the mechanisms of
orlistat with a focus on the role of beliefs and behaviour in
predicting weight loss.
5. Conclusions
To conclude, orlistat is currently the only prescribed obesity
medication available for obese patients. Although research
indicates that it can promote weight loss, there remains
problems with adherence and much variability in patient
outcomes. The present study aimed to explore predictors of
outcomes as a means to improve its eﬀectiveness. The results
indicate that changes in beliefs and behaviour occurring
throughout the course of taking orlistat are the best pre-
dictors of outcomes rather than baseline variables. Further,
the results indicate that those patients, who show a shift
away from a medical model of their problem towards a focus
on their own behaviour and show improvements in their
diet, lose more weight. These results have implications for
patientmanagementandtheuseoforlistatforweightloss.In
particular, orlistat causes unpleasant side eﬀects which may
cause nonadherence. However, rather than conceptualising
suchsideeﬀectsasunfortunate,theymaybethevery“active”
ingredients necessary to bring about change in patients’
behaviour. Therefore, when prescribing orlistat, clinicians
should not only alert patients to the possibility of such
consequences of eating high-fat foods, but also encourage
them to focus and learn from them in terms of what they
are eating, what this looks like when it is excluded from
their bodies, and what this would do to their bodies if it had
remained inside. Such an emphasis may encourage patients
to see these consequences of the drug if they eat a diet high
in fat, as an education, thus enabling them to take more
ownership of their weight problem, in turn facilitating and
promoting the changes in eating behaviour necessary for
both short- and longer-term weight loss and maintenance.
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